Anifrolumab Malignancy and Serious Infections Study

Summary

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.

Eligibility

Inclusion Criteria:

* First prescription of anifrolumab in the study period (no anifrolumab prescription prior to index date): date of first anifrolumab prescription will be the index date
* A minimum data availability of 12 months prior to index date
* Age ≥18 years at index date
* SLE severity: patients with moderate to severe SLE at index date
* SLE activity: patients with at least a flare (uncontrolled SLE) in the 6 months prior to index date

Exclusion Criteria:

* A diagnosis of any malignancy prior to index date
* A diagnosis of HIV/AIDS or congenital immunodeficiency prior to index date
* Organ or bone marrow transplant procedure prior to index date
* A diagnosis of serious infection in the previous 6 months

Conditions3

Interventions1

Related trials

• Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. — AstraZeneca
• Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus — AstraZeneca
• The Anifrolumab PRIM Program — AstraZeneca
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — AstraZeneca
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — AstraZeneca
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — AstraZeneca
• Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users — AstraZeneca

Browse More Trials